Avadel Pharma (AVDL) Misses Q4 EPS by 3c ; Offers Guidance

Avadel Pharma (NASDAQ: AVDL) reported Q4 EPS of ($0.05), $0.03 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $50.41 million versus the consensus estimate of $52.48 million.

GUIDANCE:

Avadel Pharma sees FY2025 revenue of $240-260 million, versus the consensus of $250.3 million.

For earnings history and earnings-related data on Avadel Pharma (AVDL) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• FDA launches Operation TrialBlazer to accelerate drug research
• Alphabet (GOOGL) call put ratio 1.6 calls to 1 put with a focus on June 22 weekly calls as share price down 6%